Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huisheng Oral Solution is a Traditional Chinese Medicine (TCM) formulation approved in China for the adjuvant treatment of various malignancies, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and gastric cancer. It is a complex multi-herb mixture containing ingredients such as *Hirudo* (leech), *Tabanus* (horsefly), *Rheum palmatum* (rhubarb), and *Prunus persica* (peach kernel). In the context of oncology, it is traditionally used to 'activate blood and remove stasis,' which translates in modern pharmacological terms to anti-angiogenic, pro-apoptotic, and immunomodulatory activities. It is frequently administered following radical surgery or alongside chemotherapy to improve long-term survival outcomes, reduce the risk of recurrence, and mitigate treatment-related side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huisheng oral solution.